Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …

Synapses are the site for brain communication where information is transmitted between
neurons and stored for memory formation. Synaptic degeneration is a global and early …

Parkinson's disease (PD) is a neurodegenerative disorder that affects millions of people
worldwide. Two hallmarks of PD are the accumulation of alpha‐synuclein and the loss of …

Decreased synaptic spine density has been the most consistently reported postmortem
finding in schizophrenia (SCZ). A recently developed in vivo measure of synaptic vesicle …

[11C] UCB-J PET for synaptic vesicle glycoprotein 2 A (SV2A) has been proposed as a
suitable marker for synaptic density in Alzheimer's disease (AD). We compared [11C] UCB-J …

Following the impressive progress in the treatment of relapsing–remitting multiple sclerosis
(MS), the major challenge ahead is the development of treatments to prevent or delay the …

Across neurodegenerative diseases, common mechanisms may reveal novel therapeutic
targets based on neuronal protection, repair, or regeneration, independent of etiology or site …

Background It has been hypothesized that the pathology of Parkinson's disease (PD)
primarily affects presynaptic terminals and spreads trans‐synaptically. Objectives The main …

In recent years, the field of neuroimaging dramatically moved forward by means of the
expeditious development of specific radioligands of novel targets. Among these targets, the …

PET technology has produced many radiopharmaceuticals that target specific brain proteins
and other measures of brain function. Recently, a new approach has emerged to image …